Newamsterdam Pharma Stock Price To Book
| NAMS Stock | 24.07 0.46 1.95% |
NewAmsterdam Pharma fundamentals help investors to digest information that contributes to NewAmsterdam Pharma's financial success or failures. It also enables traders to predict the movement of NewAmsterdam Stock. The fundamental analysis module provides a way to measure NewAmsterdam Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NewAmsterdam Pharma stock.
Price To Book Ratio is likely to gain to 3.36 in 2025. NewAmsterdam | Price To Book |
NewAmsterdam Pharma Company Price To Book Analysis
NewAmsterdam Pharma's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current NewAmsterdam Pharma Price To Book | 3.43 X |
Most of NewAmsterdam Pharma's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NewAmsterdam Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NewAmsterdam Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for NewAmsterdam Pharma is extremely important. It helps to project a fair market value of NewAmsterdam Stock properly, considering its historical fundamentals such as Price To Book. Since NewAmsterdam Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewAmsterdam Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewAmsterdam Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
NewAmsterdam Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, NewAmsterdam Pharma has a Price To Book of 3.4315 times. This is 86.64% lower than that of the Biotechnology sector and 43.19% lower than that of the Health Care industry. The price to book for all United States stocks is 63.92% higher than that of the company.
NewAmsterdam Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewAmsterdam Pharma's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics of similar companies.NewAmsterdam Pharma is currently under evaluation in price to book category among its peers.
NewAmsterdam Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NewAmsterdam Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NewAmsterdam Pharma's managers, analysts, and investors.Environmental | Governance | Social |
NewAmsterdam Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (3.38) % | ||||
| Current Valuation | 1.77 B | ||||
| Shares Outstanding | 109.82 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 99.33 % | ||||
| Number Of Shares Shorted | 2.91 M | ||||
| Price To Book | 3.43 X | ||||
| Price To Sales | 56.91 X | ||||
| Revenue | 45.56 M | ||||
| Gross Profit | 45.56 M | ||||
| EBITDA | (241.49 M) | ||||
| Net Income | (241.6 M) | ||||
| Total Debt | 448 K | ||||
| Book Value Per Share | 7.01 X | ||||
| Cash Flow From Operations | (158.56 M) | ||||
| Short Ratio | 4.40 X | ||||
| Earnings Per Share | (2.56) X | ||||
| Target Price | 45.77 | ||||
| Number Of Employees | 68 | ||||
| Beta | -0.035 | ||||
| Market Capitalization | 2.59 B | ||||
| Total Asset | 864.62 M | ||||
| Retained Earnings | (558.57 M) | ||||
| Working Capital | 756.5 M | ||||
| Net Asset | 864.62 M |
About NewAmsterdam Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.